4.7 Review

Peptide-drug conjugates as effective prodrug strategies for targeted delivery

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 110, Issue -, Pages 112-126

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2016.06.015

Keywords

Peptide-drug conjugates; Conjugated chemistry; Drug amphiphiles; Drug delivery; Cancer

Funding

  1. National Science Foundation [DMR 1255281]
  2. National Institutes of Health [NIH/ R21CA191740]
  3. Cohen Translational Fund
  4. Direct For Mathematical & Physical Scien
  5. Division Of Materials Research [1255281] Funding Source: National Science Foundation

Ask authors/readers for more resources

Peptide-drug conjugates (PDCs) represent an important class of therapeutic agents that combine one or more drug molecules with a short peptide through a biodegradable linker. This prodrug strategy uniquely and specifically exploits the biological activities and self-assembling potential of small-molecule peptides to improve the treatment efficacy of medicinal compounds. We review here the recent progress in the design and synthesis of peptide-drug conjugates in the context of targeted drug delivery and cancer chemotherapy. We analyze carefully the key design features in choosing the peptide sequence and linker chemistry for the drug of interest, as well as the strategies to optimize the conjugate design. We highlight the recent progress in the design and synthesis of self-assembling peptide-drug amphiphiles to construct supramolecular nanomedicine and nanofiber hydrogels for both systemic and topical delivery of active pharmaceutical ingredients. (C) 2016 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available